Sohini Das

Auto registrations hit record 28 mn in 2025, EV sales steal the spotlight

India's vehicle registrations crossed 28 million in calendar year 2025 for the first time, driven by steady overall demand and strong growth in electric two-wheelers and passenger EVs

A silent attrition of women doctors ails India's healthcare system

A silent attrition is hollowing out India's healthcare workforce, with implications for patient care and equity

Pharma leaders flag quality, sustainability as export priorities for 2026

At Pharmexcil's 2025 AGM, industry leaders stressed a shift from volume-led growth to quality, sustainability and market diversification as India's pharma export strategy looks ahead to 2026

Healthcare IPO count jumps in 2025; fundraising flat, returns soften

The surge has come alongside a decline in average issue sizes and more muted listing-day returns compared with last year

EV resale: Automakers launch buybacks, battery health checks to win buyers

Car OEMs are going beyond the initial purchase, institutionalising battery health checks and resale benchmarks to ease depreciation and battery-life concerns for EV buyers

Rising input costs may squeeze margins of Indian auto, component makers

A rally in aluminium, copper and platinum group metals is offsetting softer steel and rubber prices, raising fresh margin risks for automakers and suppliers amid weak pricing power

Floor price for API imports may boost local offtake of pharma inputs

DGFT's floor prices on select bulk drugs aim to curb Chinese dumping, support PLI-backed manufacturers and lift domestic offtake, though capped medicine prices may limit cost pass-through

Delhi pollution curbs open new market for ICE-to-EV retrofitters

Delhi's tighter pollution norms are boosting demand for EV retrofits, but industry players are urging the government to cut GST and ease regulatory hurdles to scale up conversions

H5N1 adapts to cattle, raising red flags for India's avian flu preparedness

New study finds avian influenza virus is becoming better adapted to infect mammals

Revving up: Volkswagen group rolls out VRS for production site workers

Skoda Auto Volkswagen India says it has introduced a voluntary retirement scheme at its Pune and Chhatrapati Sambhaji Nagar plants after union requests

Ajanta Pharma sets aside ₹1K crore for acquisitions to plug therapy gaps

Pain management, dermatology, nephrology and gynaecology are emerging as key focus areas

French drugmaker Servier sharpens India strategy, eyes ₹1,000 cr revenue

Servier is stepping up its India push to bring first-in-class and precision medicines, expand global clinical research participation and use India for manufacturing and GCC services

Electric vehicle sales top 2 million in the first 11 months of 2025

PVs grow 77.5% while 2Ws post 9.85% growth

GST 2.0 tilts scales towards ICE; electric vehicle penetration softens

Electric car sales grew by 63% YoY in November; but penetration fell to 3.7% below the pre-GST rate cut level of 5%

Even today, I think BBL at $5.5 billion is undervalued: Kiran Mazumdar-Shaw

'Can reinvest operating cash back into biz to scale up GLP-1s'

Biocon to integrate Biocon Biologics in $5.5-bn tranx, pivots away from IPO

Proposed transaction will result in Biocon Biologics becoming a wholly-owned subsidiary of Biocon, simplifying the group structure, and strengthening the consolidated balance sheet

SKF India Industrial expects top line to nearly double in 5 years

SKF India Industrial expects revenue to scale to about ₹4,500 crore in five years, with margins improving post-2028 as a Pune plant-led capex cycle is completed and efficiency rises

Biocon board to weigh BBL stake buyout, fundraising options on December 6

Biocon's board will meet on December 6 to consider acquiring Biocon Biologics shares from minority investors through cash or a share swap, and to approve fundraising options such as QIP, rights issue

Manipal Health readies $1 bn IPO; targets $12-15 bn valuation

Valuation of India's largest hospital network is around $12-15 bn. The Issue will comprise fresh issue of shares and a small portion as OFS

Pharmaceutical sector set to gain from rupee fall despite API dependence

Exporters like Sun Pharma, Dr Reddy's may see 7-8% revenue lift, yet margins pressured by high raw material import costs